NUMD - Nu-Med Plus, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.00 (0.00%)
At close: 11:32AM EDT
Stock chart is not supported by your current browser
Previous Close1.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Avg. Volume1,559
Market Cap38.003M
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire12 hours ago

    Nu-Med Plus, Inc. Strategically Positioned After Monopoly-Ending Patent Ruling Opens Nitric Oxide Market

    A Federal Circuit Court ruling in May invalidated the majority of a patent for a dominant nitric oxide producer, which allowed a single company to sell nitric oxide gas for medical use. Now other gas supply companies are expected to enter and expand the medical nitric oxide market. With the monopoly broken the resulting market expansion will result in a greater demand for Nu-Med Plus delivery devices explains Jeff Robins, CEO of Nu-Med Plus.

  • GlobeNewswire15 days ago

    Nu-Med Plus, Inc. Approaches Landmark Certification to Speed New Nitric Oxide Medical Device Approval 

    The announcement comes in anticipation of near-term FDA 510(k) fillings for Nu-Med Plus nitric oxide delivery devices. ISO 13485 is an international standard that specifies requirements for a quality management system for design, development and manufacture of medical devices.

  • GlobeNewswire2 months ago

    Nu-Med Plus, Inc. Selects s2s Public Relations firm as its Strategic Partner

    The firm produces compelling public relations campaigns and social media strategies that will help drive awareness of Nu-Med Plus and its innovative approach to nitric oxide delivery. The team of former journalists, startup executives, and public relations practitioners will further help guide the expansion of Nu-Med Plus, Inc. and its Inhaled Nitric Oxide(INO) products throughout the financial arena.

  • GlobeNewswire2 months ago

    Nu-Med Plus, Inc. engages Millennium Biosciences for Quality and Regulatory consulting services

    Nu-Med Plus, Inc. (NUMD), a medical device company which investigates and develops applications of Nitric Oxide technologies in the medical field, has selected Millennium Biosciences as their strategic partner for company quality and regulatory service.  Mr. Mike D’Amico who leads Millennium has been a successful, focused, quality-driven scientific leader with global strategic Quality systems and Regulatory experience within the scientific community. Inhaled Nitric oxide(INO) is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems and may have future applications for a variety of other diseases and medical complications that are currently being investigated.

  • GlobeNewswire2 months ago

    Nu-Med Plus Inc. applies for Innovative Patent on Reactive Tube Coating

    Nu-Med Plus, Inc. (NUMD), a medical device company which explores and develops medical applications of new technologies in the medical field, announced its patent filing for its pioneering chemically reactive coating. The coating ensures that only a contaminant free nitric oxide, a life saving drug for neonates, reaches the patient. Nu-Med Plus has developed a distinctive method for a reactive coating that chemically bonds or adheres to the inside surface of common medical gas delivery tubing.